C Michel Zwaan

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. doi request reprint Acute leukemias in children with Down syndrome
    Michel C Zwaan
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, Rotterdam, The Netherlands
    Pediatr Clin North Am 55:53-70, x. 2008
  2. doi request reprint Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study
    Marjolein Blink
    Haematologica 99:299-307. 2014
  3. pmc Assessing children's competence to consent in research by a standardized tool: a validity study
    Irma M Hein
    Department of Child and Adolescent Psychiatry and de Bascule, Academic Medical Center Amsterdam, Meibergdreef 5, Amsterdam, 1105, AZ, The Netherlands
    BMC Pediatr 12:156. 2012
  4. doi request reprint Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium
    C Michel Zwaan
    Erasmus Medical Center, Sophia Children s Hospital, Rotterdam, The Netherlands
    J Clin Oncol 31:2460-8. 2013
  5. doi request reprint The role of the 'innovative therapies for children with cancer' (ITCC) European consortium
    C Michel Zwaan
    Dept of Ped Oncology Hematology, Erasmus MC Sophia Children s Hospital, GJ Rotterdam, The Netherlands
    Cancer Treat Rev 36:328-34. 2010
  6. doi request reprint Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study
    Christian M Zwaan
    Department of Paediatric Oncology Haematology, Sophia Children s Hospital, Erasmus Medical Centre, Rotterdam, The Netherlands
    Br J Haematol 148:768-76. 2010
  7. doi request reprint Acute leukemias in children with Down syndrome
    C Michel Zwaan
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, Rotterdam, The Netherlands
    Hematol Oncol Clin North Am 24:19-34. 2010
  8. pmc Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study
    Eva A Coenen
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 117:7102-11. 2011
  9. pmc Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia
    Brian V Balgobind
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Haematologica 96:1478-87. 2011
  10. doi request reprint CBL mutations do not frequently occur in paediatric acute myeloid leukaemia
    Eva A Coenen
    Department of Paediatric Oncology Haematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Br J Haematol 159:577-84. 2012

Detail Information

Publications26

  1. doi request reprint Acute leukemias in children with Down syndrome
    Michel C Zwaan
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, Rotterdam, The Netherlands
    Pediatr Clin North Am 55:53-70, x. 2008
    ..Twenty percent of children with transient leukemia subsequently develop myeloid leukemia. This transition offers a unique model to study the stepwise development of leukemia, and of gene dosage effects mediated by aneuploidy...
  2. doi request reprint Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study
    Marjolein Blink
    Haematologica 99:299-307. 2014
    ....
  3. pmc Assessing children's competence to consent in research by a standardized tool: a validity study
    Irma M Hein
    Department of Child and Adolescent Psychiatry and de Bascule, Academic Medical Center Amsterdam, Meibergdreef 5, Amsterdam, 1105, AZ, The Netherlands
    BMC Pediatr 12:156. 2012
    ..A gold standard for competence assessment in children does not exist. In this article we describe a study protocol on the development of a standardized tool for assessing competence to consent in research in children and adolescents...
  4. doi request reprint Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium
    C Michel Zwaan
    Erasmus Medical Center, Sophia Children s Hospital, Rotterdam, The Netherlands
    J Clin Oncol 31:2460-8. 2013
    ..This phase I study of the Innovative Therapies for Children with Cancer Consortium assessed dasatinib safety and efficacy in pediatric patients...
  5. doi request reprint The role of the 'innovative therapies for children with cancer' (ITCC) European consortium
    C Michel Zwaan
    Dept of Ped Oncology Hematology, Erasmus MC Sophia Children s Hospital, GJ Rotterdam, The Netherlands
    Cancer Treat Rev 36:328-34. 2010
    ..Through proper evaluation in collaborative clinical trials we will learn how best to use these new therapeutic approaches and improve the survival rates and reduce toxicity for children with cancer...
  6. doi request reprint Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study
    Christian M Zwaan
    Department of Paediatric Oncology Haematology, Sophia Children s Hospital, Erasmus Medical Centre, Rotterdam, The Netherlands
    Br J Haematol 148:768-76. 2010
    ..This study showed a favourable safety/efficacy profile of single-agent GO in children with refractory first or second relapse of AML...
  7. doi request reprint Acute leukemias in children with Down syndrome
    C Michel Zwaan
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, Rotterdam, The Netherlands
    Hematol Oncol Clin North Am 24:19-34. 2010
    ..Twenty percent of children with transient leukemia subsequently develop myeloid leukemia. This transition offers a unique model to study the stepwise development of leukemia and of gene dosage effects mediated by aneuploidy...
  8. pmc Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study
    Eva A Coenen
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 117:7102-11. 2011
    ..003) in univariate analysis only. In conclusion, like TP, specific ACAs have independent prognostic significance in pediatric 11q23/MLL-rearranged AML, and the mechanism underlying these prognostic differences should be studied...
  9. pmc Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia
    Brian V Balgobind
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Haematologica 96:1478-87. 2011
    ..However, there has been no recent comprehensive overview of these genetic aberrations in one large pediatric acute myeloid leukemia cohort...
  10. doi request reprint CBL mutations do not frequently occur in paediatric acute myeloid leukaemia
    Eva A Coenen
    Department of Paediatric Oncology Haematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Br J Haematol 159:577-84. 2012
    ..In conclusion, we report a very low CBL mutation frequency in paediatric AML, which, together with the lack of difference in protein and mRNA expression, illustrates the limited role of CBL in paediatric AML...
  11. doi request reprint Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique
    Brian V Balgobind
    Paediatric Oncology Haematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Eur J Cancer 46:1892-9. 2010
    ..Larger prospective studies are needed to further define the prognostic relevance of MLL-PTD in paediatric AML...
  12. doi request reprint High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)
    Jenny E Kuipers
    Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 117:928-35. 2011
    ..70 vs 0.37, P = .03) In conclusion, we identified IGSF4 overexpression to be discriminative for t(9;11)(p22;q23) patients with FAB-M5, regulated partially by promoter methylation and resulting in survival benefit...
  13. pmc Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia
    Iris H I M Hollink
    Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Haematologica 96:384-92. 2011
    ..Our objective was to investigate the characteristics, gene expression profiles and prognostic impact of the different CEBPA aberrations in pediatric acute myeloid leukemia...
  14. pmc Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group
    Trudy D Buitenkamp
    Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 123:70-7. 2014
    ..Future strategies to improve outcome in DS-ALL should include improved supportive care throughout therapy and reduction of therapy in newly identified good-prognosis subgroups. ..
  15. doi request reprint Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia
    Astrid A Danen-van Oorschot
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Pediatr Blood Cancer 58:715-21. 2012
    ..Aberrant miRNA expression patterns have been found in various types of cancer. So far, information about the expression of miRNAs in pediatric acute myeloid leukemia is limited...
  16. doi request reprint High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine
    Costa Bachas
    Department of Pediatric Oncology Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Blood 116:2752-8. 2010
    ..We hence propose that risk stratification, malignant cell detection, and selection of personalized treatment should be based on status of type I/II mutations both at initial diagnosis and during follow-up...
  17. doi request reprint NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern
    Iris H I M Hollink
    Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 118:3645-56. 2011
    ..Taken together, NUP98/NSD1 identifies a previously unrecognized group of young AML patients, with distinct characteristics and dismal prognosis, for whom new treatment strategies are urgently needed...
  18. doi request reprint Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group
    Eva A Coenen
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 122:2704-13. 2013
    ..In conclusion, pediatric t(8;16)(p11;p13) AML is a rare entity defined by a unique gene expression signature and distinct clinical features in whom spontaneous remissions occur in a subset of neonatal cases. ..
  19. pmc Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study
    Brian V Balgobind
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 114:2489-96. 2009
    ..Screening for these translocation partners is needed for accurate treatment stratification at diagnosis...
  20. doi request reprint Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia
    Iris H I M Hollink
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 113:5951-60. 2009
    ..001). Patients with both a WT1 mutation and a FLT3/ITD had a dismal prognosis (5-year pOS 21%). WT1 mutations occur at a significant rate in childhood AML and are a novel independent poor prognostic marker...
  21. pmc Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia
    Trudy D Buitenkamp
    Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Haematologica 95:1106-13. 2010
    ..This latter problem is assumed to be caused by a higher cellular sensitivity of tissues in children with Down syndrome. However, whether differences in pharmacokinetics play a role is unknown...
  22. doi request reprint No significant prognostic value of normal precursor B-cell regeneration in paediatric acute myeloid leukaemia after induction treatment
    Anne E Bras
    Department of Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
    Br J Haematol 161:861-4. 2013
    ..Therefore, BCP regeneration does not reflect good response to treatment in paediatric AML, possibly due to the relatively high base-line levels of BCP in children...
  23. doi request reprint KIAA1524: A novel MLL translocation partner in acute myeloid leukemia
    Eva A Coenen
    Department of Pediatric Oncology and Hematology, Sophia Children s Hospital, Rotterdam, The Netherlands
    Leuk Res 35:133-5. 2011
    ..KIAA1524 has never been related to hematologic malignancies before, and the current AML case is the first case in which an MLL-KIAA1524 fusion was described...
  24. doi request reprint NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern
    J D E de Rooij
    Department of Pediatric Hematology Oncology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 27:2280-8. 2013
    ..NUP98/JARID1A cases were characterized by HOXA/B gene overexpression, which is a potential druggable pathway. In conclusion, NUP98/JARID1A is a novel recurrent genetic abnormality in pediatric AMKL...
  25. doi request reprint Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis
    Brian V Balgobind
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 111:4322-8. 2008
    ..NF1 inactivation may provide an additional proliferative signal toward the development of leukemia...
  26. doi request reprint In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia
    Irene Homminga
    Department of Pediatric Hemato Oncology, Erasmus MC Rotterdam Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 118:2184-90. 2011
    ..We conclude that especially T-ALL, but also BCP-ALL, pediatric patients may benefit from forodesine or nelarabine (ara-G) treatment...